羅索沙星在抑制三陰性乳癌的轉移上的用途

專利類型

發明

專利國別 (專利申請國家)

中華民國

專利申請案號

111149673

專利證號

I 804455

專利獲證名稱

羅索沙星在抑制三陰性乳癌的轉移上的用途

專利所屬機關 (申請機關)

國立陽明交通大學

獲證日期

2023/06/01

技術說明

在台灣或是美國，乳癌發生率居女性10大癌症之冠，相較其他癌症，多元的治療方針使得乳癌早期能夠接近完全治癒的療效，根據世界衛生組織（WHO）預測報告指出，截至2025年全球將有高達1,882萬名乳癌病患。在乳癌目前四大亞型分類中，三陰性乳癌具有高死亡率、高復發性和高腦部轉移特性，並且好發於較年輕的女性，約有15%的乳癌屬於此類，但是目前臨床上仍缺乏治療三陰性乳癌的標靶藥物。本專利是第一個提出Rosoxacin能有抑制三陰性乳癌轉移，細胞實驗證實其可有效抑制三陰性乳癌轉移，且相較於Rosoxacin之其他代藥物，顯著抑制三陰性乳癌轉移，將可作為臨床上治療三陰性乳癌之藥物。 In Taiwan or the United States, the incidence of breast cancer ranks first among the top 10 cancers in women. Compared with other cancers, multiple treatment strategies make early breast cancer close to complete cure. According to the report of the World Health Organization (WHO). By 2025, there will be as many as 18.82 million breast cancer patients worldwide. Among the current four major subtypes of breast cancer, triple-negative breast cancer (TNBC) has the characteristics of high mortality, high recurrence, and high brain metastasis, and it is more likely to occur in younger women. About 15% of breast cancers belong to this category, but the current clinical There is still a lack of targeted drugs for the treatment of TNBC. This patent is the first to propose that Rosoxacin can inhibit the metastasis of TNBC. Cell-based experiments have confirmed that it can effectively inhibit the metastasis of TNBC. Compared with other generation drugs of Rosoxacin, it can significantly inhibit the metastasis of TNBC. It will be used as a clinical drugs for the treatment of TNBC.